The Southern Medical Journal (SMJ) is the official, peer-reviewed journal of the Southern Medical Association. It has a multidisciplinary and inter-professional focus that covers a broad range of topics relevant to physicians and other healthcare specialists.

SMJ // Article

Review Article

Aprocitentan: A New Option for Resistant Hypertension and Its Place in Patient Care

Authors: Jason Powell, PharmD, BCACP, Jim Taylor, PharmD

Abstract

Hypertension affects approximately 47.7% of US adults, with higher rates observed in men (50.8%) compared with women (44.6%). Risk factors and characteristics such as age, family history, race, and ethnicity also can increase the risk of developing high blood pressure and can make treatment more difficult. Aprocitentan is the first dual endothelin receptor antagonist approved for the treatment of resistant hypertension. The PRECISION clinical trial resulted in a mean change in office systolic blood pressure at 4 weeks of -15.3 mm Hg for aprocitentan 12.5 mg, -15.2 mm Hg for aprocitentan 25 mg, and -11.5 mm Hg for placebo, for a difference versus placebo of -3.8 mm Hg (97.5% confidence interval -6.8 to -0.8, P = 0.0042) and -3.7 (1.3) mm Hg (97.5% confidence interval -6.7 to -0.8, P = 0.0046), respectively. Aprocitentan has shown benifit in further reduction of blood pressure for individuals who have failed standard triple therapy, such as a combination of an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker, nondihydropyridine calcium channel blocker, and thiazide or thiazide.
Posted in: Hypertension18

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Fryar CD, Kit B, Carroll MD, et al. Hypertension prevalence, awareness, treatment, and control among adults age 18 and older: United States, August 2021-August 2023. NCHS Data Brief 2024;511:CS354233. https://www.cdc.gov/nchs/products/databriefs/db511.htm. Published October 2024. Accessed March 23, 2026.
 
2. Jones DW, Ferdinand KC, Taler SJ, et al. AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Hypertension 2025;82:e212-e316. 2025.
 
3. Centers for Disease Control and Prevention. High blood pressure risk factors. https://www.cdc.gov/high-blood-pressure/risk-factors/index.html. Published December 13, 2024. Accessed October 28, 2025.
 
4. Tryvio [package insert]. Radnor, PA: Idorsia Pharmaceutical; 2024.
 
5. Singh B, Cusick AS, Goyal A, et al. ACE inhibitors. In: StatPearls. NCBI Bookshelf version. StatPearls Publishing;2025. https://www.ncbi.nlm.nih.gov/books/NBK430896. Accessed April 7, 2026.
 
6. Patel P, Launico MV. Angiotensin II receptor blockers (ARB). In: StatPearls. NCBI Bookshelf version. StatPearls Publishing;2025. https://www.ncbi.nlm.nih.gov/books/NBK537027. Accessed April 7, 2026.
 
7. McKeever RG, Patel P, Hamilton RJ. Calcium channel blockers. In: StatPearls. NCBI Bookshelf version. StatPearls Publishing;2024. https://www.ncbi.nlm.nih.gov/books/NBK482473. Accessed April 7, 2026.
 
8. Hughes J, Lockhart J, Joyce A. Do calcium antagonists contribute to gastro-oesophageal reflux disease and concomitant noncardiac chest pain? Br J Clin Pharmacol 2007;64:83-89.
 
9. Rivera A, Montoya E, Varon J. Intravenous clevidipine for management of hypertension. Integr Blood Press Control 2010;3:105-111.
 
10. Arumugham VB, Shahin MH. Therapeutic uses of diuretic agents. In: StatPearls. NCBI Bookshelf version. StatPearls Publishing;2023. Accessed April 7, 2026. https://www.ncbi.nlm.nih.gov/books/NBK557838.
 
11. Nachawati D, Leslie SW, Patel JB. Alpha-blockers. In: StatPearls. NCBI Bookshelf version. StatPearls Publishing;2025. Accessed April 7, 2026. https://www.ncbi.nlm.nih.gov/books/NBK556066.
 
12. UpToDate Lexidrug. Silodosin. https://www.uptodate.com/.contents/silodosin-drug-information. Accessed November 12, 2025.
 
13. Dean JS, II Reddivari AKR. Alpha-1 receptor agonists. In: StatPearls. NCBI Bookshelf version. StatPearls Publishing;2023. Accessed April 7, 2026. https://pubmed.ncbi.nlm.nih.gov/31869162.
 
14. UpToDate Lexidrug. Spironolactone. https://www.uptodate.com/contents/spironolactone-drug-information. Accessed November 12, 2025.
 
15. Jones DW, Ferdinand KC, Taler SJ, et al. AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Hypertension 2025;87:e1-e130. 2025.
 
16. Farzam K, Jan A. Beta blockers. In: StatPearls. NCBI Bookshelf version. StatPearls Publishing;2023. https://www.ncbi.nlm.nih.gov/books/NBK532906/. Accessed April 7, 2026.
 
17. Lehtonen A. Effect of beta blockers on blood lipid profile. Am Heart J 1985;109( 5 Pt 2:1192-1196.
 
18. Klapholz M. Beta-blocker use for the stages of heart failure. Mayo Clin Proc 2009;84:718-729.
 
19. Fongemie J, Felix-Getzik E. A review of nebivolol pharmacology and clinical evidence. Drugs 2015;75:1349-1371.
 
20. UpToDate Lexidrug. Aliskiren. https://www.uptodate.com/.contents/aliskiren-drug-information. Accessed November 12, 2025.
 
21. Cohn JN, McInnes GT, Shepherd AM. Direct-acting vasodilators. J Clin Hypertens (Greenwich) 2011;13:690-692.
 
22. UpToDate Lexidrug. Minoxidil. https://www.uptodate.com/contents/minoxidil-systemic-drug-information. Accessed November 12, 2025.
 
23. Schlaich MP, Bellet M, Weber MA, et al. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet 2022;400:1927-1937.
 
24. GoodRx. 2026. Tryvio 2026 prices, coupons, and savings. https://www.goodrx.com/tryvio?srsltid=AfmBOor7Akki8M-7xgO2J8LhI1DJDW0qreTQWj4wBF9FNmY0u2ouzxRV. Accessed April 7, 2026.